Baloxavir for influenza: Enrichment obscured lack of effect in North-American adults. Author's reply

被引：1

作者：

de Haas, Esther C. ^{[1
]}

Luijendijk, Hendrika J. ^{[1
]}

机构：

[1] Univ Groningen, Univ Med Ctr Groningen, Dept Gen Practice & Elderly Care Med, POB 196, NL-9700 AD Groningen, Netherlands

来源：

EUROPEAN JOURNAL OF INTERNAL MEDICINE | 2020年 / 72卷

关键词：

Clinical trial; Enrichment; Generalisability; Baloxavir; Influenza;

D O I：

10.1016/j.ejim.2019.12.021

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：102 / 102

页数：1

共 6 条

[1]

de Haas Esther C., EUROPEAN J INTERNAL, V62, pe8

[2]

Genentech USA Inc, 2018, XOFL BAL MARB LAB

[3] Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents [J].

Hayden, Frederick G. ;

Sugaya, Norio ;

Hirotsu, Nobuo ;

Lee, Nelson ;

de Jong, Menno D. ;

Hurt, Aeron C. ;

Ishida, Tadashi ;

Sekino, Hisakuni ;

Yamada, Kota ;

Portsmouth, Simon ;

Kawaguchi, Keiko ;

Shishido, Takao ;

Arai, Masatsugu ;

Tsuchiya, Kenji ;

Uehara, Takeki ;

Watanabe, Akira .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (10) :913-923

[4]

Ison MG, 2018, Open Forum Infect Dis, V5, pS764

[5]

Japanese Pharmaceuticals and Medical Devices Agency, 2018, REV REP XOFL 10 MG 2

[6]

Vald ~esL, 2003, EUR J INT MED, V14, P77

← 1 →